E.P. Hamilton

1.6k citations

29 papers · 317 indexed · h-index 8

Impact in

Oncology top 10%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research

Papers in ⓘ

Oncology 21
- HER2/EGFR in Cancer Research 14
- Cancer Treatment and Pharmacology 5
- Cancer Immunotherapy and Biomarkers 4
Pulmonary and Respiratory Medicine 15
- Advanced Breast Cancer Therapies 13

Co-authors: H-T. Arkenau (2 shared papers)Anja von Heydebreck (2 shared papers)Petros Nikolinakos (1 shared paper)Kevin M. Chin (1 shared paper)L. Dirix (1 shared paper)Guy Jérusalem (1 shared paper)István Takács (1 shared paper)Y.H. Park (1 shared paper)
Journals: Annals of Oncology (18 papers)Cancer Research (5 papers)ESMO Open (3 papers)Gynecologic Oncology (1 paper)Current Medical Research and Opinion (1 paper)
Partner nations: United States United Kingdom Italy

In The Last Decade

E.P. Hamilton

26 papers receiving 313 citations

Peers

Countries citing papers authored by E.P. Hamilton

Since Specialization

Citations

This map shows the geographic impact of E.P. Hamilton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.P. Hamilton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.P. Hamilton more than expected).

Fields of papers citing papers by E.P. Hamilton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.P. Hamilton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.P. Hamilton. The network helps show where E.P. Hamilton may publish in the future.

Co-authors

The 25 scholars most cited alongside E.P. Hamilton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with E.P. Hamilton Line = papers co-authored together E.P. Hamilton links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial Cancer Research ·L. Dirix, István Takács, Petros Nikolinakos, Guy Jérusalem, H-T. Arkenau, E.P. Hamilton, Anja von Heydebreck, H. Freiherr Grote, Kevin M. Chin, ME Lippman	2016	89
2	LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study Annals of Oncology ·Javier Cortés, S-B. Kim, W-P. Chung, S-A. Im, Y.H. Park, Roberto Hegg, Minjung Kim, L-M Tseng, Vanessa Petry, C-F. Chung, Hiroji Iwata, E.P. Hamilton, Giuseppe Curigliano, Binghe Xu, C. Lee, Y. Liu, Jillian Cathcart, Emarjola Bako, Sunil Verma, Sara A. Hurvitz	2021	73
3	460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers Annals of Oncology ·Komal Jhaveri, Hyo S. Han, Efrat Dotan, D-Y. Oh, C. Ferrario, Anthony W. Tolcher, Kyung-Woo Lee, C-Y. Liao, Y-K. Kang, Yeul Hong Kim, E.P. Hamilton, A. Spira, Naresh Patel, Christos S. Karapetis, Sun Young Rha, Lisa Boyken, Joseph Woolery, Phillipe Bedard	2022	44
4	162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer Annals of Oncology ·E.P. Hamilton, Charles L. Shapiro, Valentina Boni, M. Martín Jiménez, Gianluca Del Conte, J. Cortés, Laila Agrawal, H-T. Arkenau, Antoinette R. Tan, Philip R. Debruyne, Anna Minchom, Annemie Rutten, F. Valdes-Albini, Evan Y. Yu, Fumitaka Suto, F-C. Cheng, Bincy Augustine, Bi‐Hua Cheng, Daniel Barrios, S.A. Hurvitz	2022	31
5	2749 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity European Journal of Cancer ·ML Disis, M.R. Patel, S. Pant, E.P. Hamilton, A. Craig Lockhart, Karen Kelly, J. Thaddeus-Beck, M. Gordon, Glen J. Weiss, Samuel Ejadi, M.H. Taylor, K. Chin, Jean-Marie Cuillerot, Anja von Heydebreck, James L. Gulley	2015	9
6	VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer Annals of Oncology ·I. Vergote, Alejandro Pérez Fidalgo, E.P. Hamilton, Giorgio Valabrega, Toon Van Gorp, J. Sehouli, David Cibula, Tomer Levy, Stephen Welch, Debra L. Richardson, Eva María Guerra Alia, Giovanni Scambia, Sabine Henry, Pauline Wimberger, Danielle Miller, José Gil Martínez, B.J. Monk, Sharon Shacham, Mansoor Raza Mirza, V. Makker	2022	8
7	610O Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6 Annals of Oncology ·Manish Patel, E.P. Hamilton, Sarina A. Piha‐Paul, J. Henry, Udai Banerji, Mohammed Najeeb Al Hallak, Hitoshi Okada, M. Qian, X. Zhang, Nur Akmarina B.M. Said, V. Chatikhine, E. Fontana	2024	7
8	218P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Updated phase Ib cohort results ESMO Open ·E.P. Hamilton, S.A. Hurvitz, Nicholas P. McAndrew, Melinda L. Telli, Dejan Juric, Hyo S. Han, Rita Nanda, G. Zahrah, Yaowen Zhang, Weiwei Tan, Elizabeth K. Duperret, Eric Zhi, C. Mather, R. Jeselsohn	2024	7
9	205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer ESMO Open ·Sara A. Hurvitz, Anne F. Schott, X. Cynthia, Rita Nanda, G. Zahrah, N. Hunter, Adrienne Tan, Melinda L. Telli, Jesús Anampa, R. Jeselsohn, Pamela N. Münster, Eric Zhi, R. Gedrich, C. Mather, Hyo S. Han, E.P. Hamilton	2023	6
10	VP8-2021: Adjuvant abemaciclib combined with endocrine therapy (ET): Updated results from monarchE Annals of Oncology ·Joyce O’Shaughnessy, Priya Rastogi, Nadia Harbeck, Masakazu Toi, Roberto Hegg, Joohyuk Sohn, Valentina Guarneri, Javier Cortés, E.P. Hamilton, Ran Wei, Ashwin Shahir, Belén San Antonio, Sarah C. Nabinger, Sara M. Tolaney, Miguel Martín, Stephen Johnston	2021	5
11	Preferences of hxealthy men for two different endocrine treatment options offered for locally advanced prostate cancer Current Medical Research and Opinion ·Valerie Jenkins, Lesley Fallowfield, Trudi Edginton, Heather Payne, E.P. Hamilton	2005	5
12	Abstract P4-14-19: ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets) Cancer Research ·RK Murthy, E.P. Hamilton, VF Borges, SL Moulder, Nathalie Aucoin, Stephen Welch, Felipe Javier Chaves, CI Falkson, Luke Walker, Cristiano Ferrario	2016	5
13	338TiP CAPItello-292: A phase 1b/3 study of capivasertib, palbociclib and fulvestrant versus placebo, palbociclib and fulvestrant in HR+/HER2− advanced breast cancer Annals of Oncology ·E.P. Hamilton, Gaia Schiavon, Lynda Grinsted, Elza C. de Bruin, Maria Teresa Catanese, Hope S. Rugo	2021	5
14	Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers Annals of Oncology ·M. Beeram, E.P. Hamilton, Mariela Blum Murphy, Diana F. Hausman, Jeffrey R. Infante, Ron Korn, Amita Patnaik, Sarina A. Piha‐Paul, Drew Rasco, Gerry Rowse, Jamuna Thimmarayappa, Anthony W. Tolcher, Funda Meric‐Bernstam	2017	4
15	Safety and efficacy of a DKK1 inhibitor (DKN-01) as monotherapy or in combination with paclitaxel in patients with Wnt activated recurrent gynecologic malignancies Gynecologic Oncology ·Rebecca C. Arend, Cesar M. Castro, U. Matulonis, E.P. Hamilton, C.C. Gunderson, Kristopher Lybarger, Michael H. Kagey, Cynthia A. Sirard, M. J. Birrer	2019	4
16	Abstract S4-03: Exome sequencing reveals clinically actionable mutations in the pathogenesis and metastasis of triple negative breast cancer Cancer Research ·KL Blackwell, E.P. Hamilton, P. Kelly Marcom, J Peppercorn, Novera Herbert Spector, Gretchen Kimmick, JO Hopkins, Justin Favaro, Gifone Aguiar Rocha, Michelle Parks, Christopher G. Love, Paula Scotland, SS Dave	2013	3
17	LBA5_PR Abemaciclib in high risk early breast cancer Annals of Oncology ·Stephen Johnston, Nadia Harbeck, Roberto Hegg, Masakazu Toi, Miguel Martín, Zhimin Shao, Mario Campone, E.P. Hamilton, J. Sohn, Valentina Guarneri, Javier Cortés, Patrick Neven, F. Boyle, Ian C. P. Smith, Desirée Headley, Ran Wei, Martin Frenzel, Joanne Cox, J. O’Shaughnessy, Priya Rastogi	2020	2
18	258P Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC) Annals of Oncology ·Joyce O’Shaughnessy, Adam Brufsky, Hope S. Rugo, Sara M. Tolaney, Sami Diab, Kevin Punie, Sagar Sardesai, E.P. Hamilton, Delphine Loirat, TA Traina, RA Leon-Ferre, Sara A. Hurvitz, Kevin Kalinsky, Aditya Bardia, Stéphanie Henry, IA Mayer, Quan Hong, S. Phan, Javier Cortés	2021	2
19	436TiP DYNASTY-Breast02: A phase III trial of BNT323/DB-1303 vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer Annals of Oncology ·Joyce O’Shaughnessy, J. Cortés, P. Schmid, B. Xu, Zhimin Shao, Luís Augusto Teixeira, Mehmet Alı Nahıt Şendur, Dhanusha Sabanathan, S-B. Kim, M.A. Colleoni, Michael J. Wenger, Jang‐Hern Lee, Vivian W. Gu, Yang Qiu, Simin Liu, Hong Fang, Rong Shi, Zhou Zhu, E.P. Hamilton	2024	1
20	924MO First data disclosure of the first-in-class DNA polymerase theta inhibitor, ART6043, as monotherapy and in combination with olaparib, in patients with molecularly-selected advanced solid tumors Annals of Oncology ·Timothy A. Yap, N. Lakhani, Minal Barve, E.P. Hamilton, Babar Bashir, Kathleen Mackay, S K Skelton, Bryony Harrop, Nancy Little, George M. Langford, Suraj Menon, Caroline Baxter, Michaela Pentony, Peter J. Dickinson, Niall M.B. Martin, Graeme C.M. Smith, Susana Barriga, Daniel Headley, I. C. Smith, Susanna V. Ulahannan	2025	1

About E.P. Hamilton

E.P. Hamilton is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging and Immunology and Allergy, having authored 29 papers that have together received 317 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (14 papers), Advanced Breast Cancer Therapies (13 papers), Cancer Treatment and Pharmacology (5 papers), Breast Cancer Treatment Studies (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Estrogen and related hormone effects (3 papers). The work is most often cited by research in Oncology (272 citations), Radiology, Nuclear Medicine and Imaging (91 citations), Pulmonary and Respiratory Medicine (124 citations), Cancer Research (46 citations) and Genetics (26 citations). E.P. Hamilton has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include H-T. Arkenau, Anja von Heydebreck, Petros Nikolinakos, Kevin M. Chin, L. Dirix, Guy Jérusalem, István Takács, Y.H. Park, Binghe Xu and Hiroji Iwata. Their work appears in journals such as Annals of Oncology, Cancer Research, ESMO Open, Gynecologic Oncology and Current Medical Research and Opinion.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact